Sirion Therapeutics says that a late-stage study of ST-601 for eye inflammation following ocular surgery demonstrated positive results. Difluprednate demonstrated a statistically significant response over a placebo on the eighth day of dosing and maintained superiority through the 15-day treatment period. Based on the preliminary results, the Tampa-based biotech said that it would proceed with an NDA to the FDA.
- here's the release on the data
Related Articles:
Sirion completes Sytera merger. Report
Sirion licenses eye infection gel. Report